Zhitong Finance App News, Luye Pharmaceutical (02186) announced that LY03021, the next-generation central nervous system (CNS) drug under development independently developed by the Group, has obtained permission from the US Food and Drug Administration (FDA) to conduct clinical trials and is intended to be used to treat depression. According to the Group's knowledge, LY03021 is the world's first gamma-aminobutyric acid A receptor (GABAAR) positive allosteric modulator, dopamine transporter (DAT), and norepinephrine transporter (NET) inhibitor.
Depression affects a wide range of people, and the burden of illness is heavy. According to the data, about 322 million people worldwide have the disease; in 2025, about 20 million adults in the US experienced a major depressive episode in the past year. Depression often co-occurs with mental disorders such as anxiety disorder, and may be accompanied by more severe impairment of function.
Existing antidepressants generally work for 2 to 4 weeks, and it is difficult for quite a few patients to achieve complete remission; after treatment, patients may still have residual symptoms such as anxiety, lack of energy, or lack of pleasure, and drug-related adverse reactions such as sexual dysfunction may also affect treatment adherence. Furthermore, although a few fast-acting antidepressants have been approved for marketing, their clinical application has significant limitations: application scenarios are limited (requiring in-hospital supervision), and are associated with a high risk of sedation, dissociation, loss of consciousness, and abuse. Therefore, how to quickly and effectively control clinical symptoms of depression, further improve treatment efficacy and prognosis, and at the same time balance ease of use and safety has become a problem to be solved in the current development of antidepressants.
LY03021 is developed based on the Group's AI innovative drug platform TransnExceedTM. It is the first three-target antidepressant of its kind, and also acts on GABAAR, DAT, and NET. On the one hand, Ly03021 selectively targets the GABAAR synaptic α1 beta2 subtype and the extrasynaptic α4 β3 delta subtype. By regulating glutamate-GABA balance in the brain, LY03021 quickly exerts antidepressant and anxiolytic effects. Its high selectivity for extrasynaptic GABAAR subtypes reduces the risk of sedation, drowsiness, loss of consciousness, and decreased long-term efficacy due to excessive activation of intra-synaptic subtypes. On the other hand, by inhibiting DAT and NET, LY03021 increases dopamine (DA) and norepinephrine (NE) levels in the brain, and regulates reward and emotional pathways. It not only effectively relieves core symptoms of depression such as low mood and loss of interest, but also targets loss of pleasure and drug-related or associated sexual dysfunction associated with the disease itself. At the same time, DA and NE-mediated arousal effects can antagonize central inhibitory signals, mechanically reduce central inhibitory effects caused by excessive activation of GABAAR, and further optimize central safety while achieving antidepressant efficacy.
Non-clinical studies showed that LY03021 significantly improved depression and anxiety-like behavior in model animals 4 hours after administration, and the curative effect was stable until the end of the 56-day study; when administered once a week, the efficacy continued until the end of the 56-day study; when administered once a week, the efficacy continued until 7 days after medication, suggesting that LY03021 has both rapid onset and long-lasting efficacy, and supports the development of a weekly dosing regimen. At the same time, LY03021 has good safety, and its NOAEL (dose with no toxic side effects observed) is more than 50 times the effective dose; animal tests showed no withdrawal symptoms related to physical dependency.
LY03021 is another innovative drug in the CNS field developed simultaneously by the Group in China and the US. Currently, phase I clinical research is also being carried out in China. Currently, the safety and tolerability of LY03021 of 5 mg to 180 mg in a single dose is good. No adverse events of sedation, loss of consciousness, or loss of consciousness have been detected. The theory of unbalanced regulation of GABAAR subtypes within and outside synapses and coordination of the three targets has been initially verified. Non-clinical studies have suggested that the drug under development can rapidly and continuously improve depressive and anxiety-like behavior in animal models. It is expected that clinical trials can be effective for 12 hours, administered once a week, have rapid control, long-lasting effects and ease of use, and rely on a unique mechanism of action to avoid the risk of sedation, and provide a new solution for central nervous system disease treatment. The Group plans to launch the first phase II clinical trial of LY03021 in China in 2027 to explore the rapid antidepressant efficacy and safety of the weekly dosage regimen at different doses.
The Group has long been deeply involved in the field of CNS treatment. It has successfully launched a number of products in markets such as China, the United States, Europe, Japan, etc., and continues to promote the global development of next-generation innovative drugs. In addition to LY03021, the Group also has a number of new molecular entities with differentiated characteristics in the clinical phase. Among them, LY03015 is the only VMAT2/sigma-1R dual-target innovative drug in the world, intended to treat tardive dyskinesia and chorea associated with Huntington's disease. It has now completed phase II clinical trials in China and bridging studies in the US, respectively; LY03017 is a new generation of serotonin 2A receptor (5-HT2AR) inverse agonist/serotonin 2C receptor (5-HT2CR) antagonist, intended to treat psychotic disorders of Alzheimer's disease, parkinson's disease psychotic disorder, etc.; LY030 is the world's first trace amine Related receptor 1 (TAAR1) /serotonin 2C receptor (5-HT2CR) dual-target agonist, intended to treat schizophrenia, Alzheimer's disease, psychotic disorders, etc. Both LY03017 and LY03020 are in phase II clinical phase in China and approved for clinical trials in the US.